Published in Lancet on February 26, 2000
Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology (2008) 5.19
Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer (2010) 3.95
Molecular aspects of thyroid hormone actions. Endocr Rev (2010) 3.29
Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest (2003) 2.18
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08
Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest (2006) 1.37
Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer (2005) 1.34
Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest (2002) 1.24
PTTG/securin activates expression of p53 and modulates its function. Mol Cancer (2004) 1.11
Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer (2006) 1.07
Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene (2007) 1.06
PTTG: an important target gene for ovarian cancer therapy. J Ovarian Res (2008) 1.01
Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene (2011) 1.01
Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol (2006) 0.99
Radiation-induced senescence in securin-deficient cancer cells promotes cell invasion involving the IL-6/STAT3 and PDGF-BB/PDGFR pathways. Sci Rep (2013) 0.99
Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. Mol Biol Cell (2009) 0.98
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol (2009) 0.96
The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget (2015) 0.95
PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery (2013) 0.95
Expression of pituitary tumor transforming gene in human gastric carcinoma. World J Gastroenterol (2004) 0.94
The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res (2006) 0.92
Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog (2011) 0.92
Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer (2006) 0.90
PTTG1/securin modulates microtubule nucleation and cell migration. Mol Biol Cell (2011) 0.88
PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility. Oncogene (2013) 0.88
Pituitary tumor-transforming gene 1 regulates the patterning of retinal mosaics. Proc Natl Acad Sci U S A (2014) 0.87
Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription. Steroids (2006) 0.86
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol (2009) 0.84
Mitotic Origins of Chromosomal Instability in Colorectal Cancer. Curr Colorectal Cancer Rep (2007) 0.84
Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors. J Biol Chem (2011) 0.84
Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett (2010) 0.83
PTTG1 attenuates drug-induced cellular senescence. PLoS One (2011) 0.82
The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog (2006) 0.82
The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med (2008) 0.81
Effect of PTTG on endogenous gene expression in HEK 293 cells. BMC Genomics (2009) 0.81
Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer (2006) 0.81
Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors. Endocr Relat Cancer (2008) 0.80
Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer. Gastric Cancer (2015) 0.79
Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice. BMC Cancer (2012) 0.79
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol (2015) 0.79
PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling. Am J Cancer Res (2016) 0.78
Evidence for cooperative transforming activity of the human pituitary tumor transforming gene and human T-cell leukemia virus type 1 Tax. J Virol (2007) 0.78
Roles of miR-186 and PTTG1 in colorectal neuroendocrine tumors. Int J Clin Exp Med (2015) 0.78
Securin enhances the anti-cancer effects of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075) in human colorectal cancer cells. PLoS One (2012) 0.77
Integrated analysis of DNA methylation and microRNA regulation of the lung adenocarcinoma transcriptome. Oncol Rep (2015) 0.77
Methylation alterations are not a major cause of PTTG1 misregulation. BMC Cancer (2008) 0.77
Overexpression of the pituitary tumor transforming gene upregulates metastasis in malignant neoplasms of the human salivary glands. Exp Ther Med (2015) 0.76
Identification of genes and pathways associated with pancreatic ductal adenocarcinoma by bioinformatics analyses. Oncol Lett (2015) 0.76
Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease. Hered Cancer Clin Pract (2007) 0.76
Down-regulation of the oncogene PTTG1 via the KLF6 tumor suppressor during induction of myeloid differentiation. PLoS One (2013) 0.76
Towards post-genomic investigation of colorectal cancer. Lancet (2000) 0.75
Inhibition of PTTG1 expression by microRNA suppresses proliferation and induces apoptosis of malignant glioma cells. Oncol Lett (2016) 0.75
mTOR promotes pituitary tumor development through activation of PTTG1. Oncogene (2016) 0.75
Pituitary tumor-transforming gene 1 is expressed in primary ductal breast carcinoma, lymph node infiltration, and distant metastases. Dis Markers (2013) 0.75
Induction of chromosome instability and stomach cancer by altering the expression pattern of mitotic checkpoint genes in mice exposed to areca-nut. BMC Cancer (2013) 0.75
PTTG1 regulated by miR-146-3p promotes bladder cancer migration, invasion, metastasis and growth. Oncotarget (2016) 0.75
Does securin expression have significance in prognostication of oral tongue cancer? A pilot study. Eur Arch Otorhinolaryngol (2016) 0.75
Effect of computed tomography of the appendix on treatment of patients and use of hospital resources. N Engl J Med (1998) 5.86
Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development (2000) 3.91
Traumatic diaphragmatic hernia. Occult marker of serious injury. Ann Surg (1993) 3.28
Assessment of clinical skills of residents utilizing standardized patients. A follow-up study and recommendations for application. Ann Intern Med (1991) 3.23
Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1997) 2.90
Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest (2000) 2.89
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart (1999) 2.69
Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost (2006) 2.40
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab (2000) 2.27
Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess (1997) 2.20
Helical CT technique for the diagnosis of appendicitis: prospective evaluation of a focused appendix CT examination. Radiology (1997) 2.16
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci U S A (1999) 2.04
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol (2000) 2.03
Helical CT combined with contrast material administered only through the colon for imaging of suspected appendicitis. AJR Am J Roentgenol (1997) 1.98
Clonal origin of pituitary adenomas. J Clin Endocrinol Metab (1990) 1.81
Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1999) 1.78
Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab (1998) 1.74
Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med (1999) 1.72
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab (1999) 1.69
Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.68
Colon polyps in acromegaly. Ann Intern Med (1991) 1.66
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab (2008) 1.66
A comparison of intertendinous and classical approaches to popliteal nerve block using magnetic resonance imaging simulation. Anesth Analg (2002) 1.61
Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol (2001) 1.61
Ultrasonography by emergency physicians in patients with suspected cholecystitis. Am J Emerg Med (2001) 1.50
Multicenter evaluation of a colorimetric microplate antimycobacterial susceptibility test: comparative study with the NCCLS M24-P. Rinsho Byori (1996) 1.48
Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab (1998) 1.48
Dentin regeneration by dental pulp stem cell therapy with recombinant human bone morphogenetic protein 2. J Dent Res (2004) 1.46
Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology (1999) 1.45
Clinical, quality of life, and economic value of acromegaly disease control. Pituitary (2011) 1.44
Carbon dioxide insufflation vs. conventional saline irrigation for peroral video cholangioscopy. Endoscopy (2011) 1.44
Maternal occupational and hobby chemical exposures as risk factors for neural tube defects. Epidemiology (1999) 1.42
Analyses of the factors influencing bone graft infection after delayed cranioplasty. Acta Neurochir (Wien) (2006) 1.41
Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab (2000) 1.41
A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer (1996) 1.40
A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int (1999) 1.38
Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J Clin Endocrinol Metab (1998) 1.38
Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J (1997) 1.36
Pathophysiology of acromegaly. Endocr Rev (1983) 1.35
Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest (2000) 1.34
Letter: Metoclopramide and facial dyskinesia. Br Med J (1975) 1.33
Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology (1998) 1.33
Lung fibroblasts from patients with emphysema show a reduced proliferation rate in culture. Eur Respir J (2004) 1.32
Cost of care for a geographically determined population of low birthweight infants to age 8-9 years. II. Children with disability. Arch Dis Child Fetal Neonatal Ed (1996) 1.31
Plant homologues of components of MAPK (mitogen-activated protein kinase) signal pathways in yeast and animal cells. Plant Cell Physiol (1995) 1.31
Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest (1997) 1.29
Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev (2000) 1.28
Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology (2001) 1.25
Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother (1991) 1.25
Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab (2003) 1.24
Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem (2000) 1.24
A new method for extracting DNA or RNA for polymerase chain reaction. J Virol Methods (1990) 1.24
Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J Clin Invest (2000) 1.23
Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis (1992) 1.23
Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab (1981) 1.22
Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab (1995) 1.21
Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood (2001) 1.20
Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology (1998) 1.19
Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab (1999) 1.18
Lung fibroblasts from patients with emphysema show markers of senescence in vitro. Respir Res (2006) 1.18
Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A (1994) 1.18
Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest (1999) 1.17
Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab (2001) 1.17
Expression of human beta-defensin 2 (hBD-2) in Helicobacter pylori induced gastritis: antibacterial effect of hBD-2 against Helicobacter pylori. Gut (2001) 1.16
A solitary bronchial papilloma with malignant changes. Intern Med (2001) 1.15
Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol (1994) 1.14
Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest (1996) 1.14
Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep (2001) 1.13
Cost of care for a geographically determined population of low birthweight infants to age 8-9 years. I. Children without disability. Arch Dis Child Fetal Neonatal Ed (1996) 1.13
Relative increase in insulin-like growth factor I messenger ribonucleic acid levels in compensatory renal hypertrophy. Endocrinology (1987) 1.11
Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol Endocrinol (1998) 1.11
Current management practices for acromegaly: an international survey. Pituitary (2011) 1.10
Pituitary cytokine and growth factor expression and action. Endocr Rev (1997) 1.10
Somatotroph insulin-like growth factor-I signaling. Ann N Y Acad Sci (1993) 1.09
Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst (1999) 1.09
Placental iodothyronine deiodinase expression in normal and growth-restricted human pregnancies. J Clin Endocrinol Metab (2003) 1.09
Coffin-Siris syndrome is a SWI/SNF complex disorder. Clin Genet (2013) 1.08
Delayed appendectomy for appendicitis: causes and consequences. Am J Emerg Med (1996) 1.08
Ultrasonography by emergency physicians in patients with suspected ureteral colic. J Emerg Med (1999) 1.08
Stump appendicitis diagnosed preoperatively by computed tomography. Am J Emerg Med (1998) 1.08
Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab (1991) 1.07
Management of pituitary tumors. Ann Intern Med (1998) 1.07
Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. J Clin Invest (1995) 1.07
Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis (2006) 1.06
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest (1997) 1.06
Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene (2007) 1.06
Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation (1982) 1.05
Japanese multicenter experience of endoscopic necrosectomy for infected walled-off pancreatic necrosis: The JENIPaN study. Endoscopy (2013) 1.05
Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol (2000) 1.05
Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology (2005) 1.05
Statistical association between cancer incidence and major-cause mortality, and estimated residential exposure to air emissions from petroleum and chemical plants. Environ Health Perspect (1984) 1.04
Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology (2005) 1.04